Given this, AXL is a promising therapeutic target, and R428 (bemcentinib), a first-in-class AXL kinase inhibitor, is currently being evaluated in phase 2 clinical trials for metastatic lung and triple-negative breast cancer, glioblastoma, and acute myeloid leukemia [20, 21]. Here, AXL is linked to glioblastoma.